Longitudinal humoral and cell-mediated immune responses in a population-based cohort in Zurich, Switzerland between March and June 2022 - evidence for protection against Omicron SARS-CoV-2 infection by neutralizing antibodies and spike-specific T-cell responses.

"Declarations of competing interest The authors have no competing interests to declare."

"Funding The Corona Immunitas research network is coordinated by the Swiss School of Public Health (SSPH+) and funded by fundraising of SSPH+, including funds of the Swiss Federal Office of Public Health and private funders (ethical guidelines for funding stated by SSPH+ were respected), by funds of the cantons of Switzerland (Vaud, Zurich, and Basel), and by institutional funds of the Universities."

"Ethical approvalWe obtained written, informed consent from all participants upon study enrollment. Participants were compensated with a flat fee for any travel expenses related to study visits but otherwise did not receive any compensation for their participation. The study protocol was approved by the Cantonal Ethics Committee of Zurich (BASEC Registration No. 2020-01247) and registered (ISRCTN registry 18181860, date of registration 13 July 2020, retrospectively registered)."